Pivotal Therapeutics announces issuance of U.S. Patent 8,715,648 for its unique 6:1 EPA:DHA formulation

SOURCE: Pivotal Therapeutics Inc.

For further information: Company Contacts: Rachelle MacSweeney, President and Chief Operating Officer, Phone: 905-856-9797, E-Mail: rmacsweeney@pivotaltherapeutics.us; Kristine DiMatteo, Communications and Public Relations Manager, Phone: 905-856-9797 ext. 231, E-Mail: kdimatteo@pivotaltherapeutics.us; www.pivotaltherapeutics.us

RELATED LINKS
www.pivotaltherapeutics.us

Organization Profile

Pivotal Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890